A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer

This is a phase II, multicentre clinical study investigating HS-20093 or SHR2554 in combination with a Novel Hormonal Agent (NHA) for advanced prostate cancer. The trial comprises two cohorts.

Trial Details

NCT ID
NCT07230106
Phase
PHASE2
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • HS-20093 for Injection
  • SHR3680 Tablet
  • Abiraterone Tablet
  • SHR2554 Tablet
  • Enzalutamide Tablet
  • Darotamine Capsule
Locations (sample)
  • Nanjing, Jiangsu, China|32.06167,118.77778
  • Tianjin, Tianjin Municipality, China|39.14222,117.17667

Key Eligibility Criteria

  • Voluntarily participate in this clinical study, understand the research procedures, and are able to provide written informed consent.
  • Aged 18 to 80 years (inclusive), male.
  • ECOG performance status of 0 or 1.
  • Expected survival time ≥12 weeks.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →